nicotine has been researched along with buspirone in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Howard, JL; Pollard, GT | 1 |
| Delcore, MG; Hilleman, DE; Mohiuddin, SM | 1 |
| Damaj, MI; Glennon, RA; Martin, BR | 1 |
| Brown, HV; Daims, RM; Olmstead, RE; Schneider, NG; Sloan, K; Steinberg, C | 1 |
| Bruckmann, W; De Vry, J; Rutten, K; Tzschentke, TM; Van Der Kam, EL | 1 |
| Levin, ED | 1 |
| Fivel, PA; Kohut, SJ; Mello, NK | 1 |
| Hawkey, AB; Hoeng, J; Koshibu, K; Levin, ED; Peitsch, MC | 1 |
2 trial(s) available for nicotine and buspirone
| Article | Year |
|---|---|
Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine, and buspirone in smoking cessation.
Topics: Administration, Cutaneous; Adult; Behavior Therapy; Buspirone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nicotine; Smoking; Smoking Cessation | 1994 |
Efficacy of buspirone in smoking cessation: a placebo-controlled trial.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Buspirone; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome | 1996 |
14 other study(ies) available for nicotine and buspirone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
The staircase test: some evidence of nonspecificity for anxiolytics.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Buspirone; Drug Evaluation, Preclinical; Ethanol; Male; Meprobamate; Mice; Morphine; Motor Activity; Nicotine; Pyrimidines | 1986 |
Drug watch providing essential information.
Topics: Buspirone; Humans; Lactation; Metronidazole; Neoplasms; Nicotine; Paclitaxel; Substance-Related Disorders; Vitamin K | 1994 |
Involvement of the serotonergic system in the hypoactive and antinociceptive effects of nicotine in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Buspirone; Ketanserin; Locomotion; Male; Mice; Mice, Inbred ICR; Nicotine; Nociceptors; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Spiperone | 1994 |
The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates conditioned place preference induced by various addictive and non-addictive drugs in rats.
Topics: Animals; Brain; Buspirone; Choice Behavior; Clonidine; Cocaine; Conditioning, Classical; Dose-Response Relationship, Drug; Drug Synergism; Illicit Drugs; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Nicotine; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Social Environment; Substance-Related Disorders | 2011 |
Zebrafish assessment of cognitive improvement and anxiolysis: filling the gap between in vitro and rodent models for drug development.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Attention; Buspirone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Exploratory Behavior; Mecamylamine; Neurochemistry; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Space Perception; Time Factors; Zebrafish | 2011 |
Effects of chronic buspirone treatment on nicotine and concurrent nicotine+cocaine self-administration.
Topics: Animals; Anti-Anxiety Agents; Buspirone; Cocaine; Conditioning, Operant; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Macaca mulatta; Nicotine; Nicotinic Agonists; Reinforcement Schedule; Self Administration | 2013 |
Subchronic effects of plant alkaloids on anxiety-like behavior in zebrafish.
Topics: Alkaloids; Anabasine; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Buspirone; Carbolines; Cotinine; Disease Models, Animal; Female; Harmine; Humans; Male; Nicotine; Pyridines; Solanaceae; Zebrafish | 2021 |